MedTrace Logo

The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis

NCT05356793 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-14

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the efficacy of Sasch1, a novel anti-infective eyedrop, in the treatment of acute infectious conjunctivitis.

Conditions

  • Acute Infectious Conjunctivitis (Disorder)

Interventions

DRUG

SCH-1

Novel anti-infective eyedrop

DRUG

Placebo

SCH-1 vehicle minus active components eyedrop

Sponsors & Collaborators

  • Sacsh

    lead INDUSTRY

Principal Investigators

  • David Ritterband, MD · Sacsh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-03-28
Completion
2022-03-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05356793 on ClinicalTrials.gov